Sažetak
Researchers around the world have experienced the dual nature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ‘tragically lethal in some persons and surprisingly benign in others’. They have congregated to study novel coronavirus disease (COVID-19), a disease that mainly attacks the lungs, but also has mystifying effects on the heart, kidneys and brain. Researchers are also gathering information to determine what actually kills COVID-19 patients, whether respiratory disorder or coagulation disorder or multi organ failure. Various laboratory parameters like lactate, ferritin, hypoalbuminemia have been established as risk factor or associated with poor outcomes, but yet could not be substantiated with the scientific biochemical rationale.
SARS-CoV-2 affects the alveolar type II epithelial cells, that significantly disturbs its surfactant homeostasis, deprive Na,K-ATPase of ATP, thereby disturbing the alveolar lining fluid which then gradually decreases the alveolar gaseous exchange initiating intracellular hypoxic conditions. This activates AMP-activated kinase, which further inhibits Na,K-ATPase, that can progressively cause respiratory distress syndrome.
The virus may infect endothelial cell (EC), which being low energetic, cannot withstand the huge energy requirement towards viral replication, and therefore glycolysis, the prime energy generating pathway, has to mandatorily be upregulated, which can be achieved by Hypoxia-inducible factor 1 (HIF-1). However, HIF-1 activates transcription of von Willebrand factor, plasminogen activator inhibitor-1, and suppresses the release of thrombomodulin, thereby setting off the coagulation cascade that leads to in-situ pulmonary thrombosis and micro clots.
The proposed HIF-1 hypothesis can rationalize various features, clinical laboratory as well as autopsy findings such as respiratory distress syndrome, increased blood ferritin and lactate levels, endothelial invasion, in-situ pulmonary thrombosis and micro clots, and multiorgan failure in COVID -19
Keywords: novel coronavirus, COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, hypoxia-inducible factor-1
Ključne reči
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.